Page Title Banner (2)

8.00 - 13.00 EDT | 13:00 - 18:00 GMT

* Please note that the following agenda timings are Eastern Daylight Time.  

8:00 am Login & Join Our Coffee Chat Room

8:30 am Chair’s Opening Remarks

Revolutionizing PK/PD & Efficacy Studies in Humanized Models

8:40 am Human-Specific Immunotherapeutics Evaluation in VISTA & GITR Humanized Mouse Model

  • Ludovic Bourre Senior Director, Scientific Engagement, Crown Bioscience Inc.

Synopsis

  • Efficacy evaluation of anti-hGITR and anti-hVISTA as single agent or in combination with anti-mPD1 on MC38 tumor model 
  • Immunoprofiling: dissecting the mechanism oaction (MOA) 

9:00 am Pept-insTM, First-in-Class Technology Targeting Broad Disease Areas & High-Value Undruggable Targets

Synopsis

  • Assessing the mode of action of novel Pept-insTM utilizing the aggregation prone sequences 
  • In vivo proof-of concept using Vascin Pep-inTM targeting VEGFR2 
  • Pept-insTM as opportunities against high-value undruggable targets 

9:20 am Physiologically Relevant Mouse Models to Investigate PK & Efficacy of HSA-Based Drugs

  • Ken Howard Associate Professor, Head of Bioengineered Drug Delivery Designs Laboratory iNANO, Aarhus University

Synopsis

  • FcRn-driven cellular recycling facilitates the prolonged circulation of HSA 
  • Models that maintain autologous HSA and human FcRn receptor (hFcRn) engagement are required to avoid competition from endogenous mouse albumin 
  • Double transgenic HSA, hFcRn mice provides a physiological relevant environment and appropriate endogenous HSA competition to investigate recombinant HSA-drugs or conventional drugs whose PK is influenced by association with HSA 

9:40 am Spotlight: Immunocompetent Humanized Mouse Models for Profiling T Cell Engagers & Bispecific Antibodies

Synopsis

Relevance of model design on preclinical model performances for assessment of biologics efficacy

10:00 am Engraftment of AML-PDX: Selection of Strains of Immunocompromised Mice & Induction of Human Cytokine Release Syndrome in Humanized BRGSF Mice

  • Annie An Associate Director, Crown Bioscience, Inc.
  • Dean Campbell Director, Scientific Engagement, Crown Bioscience, Inc.

Assessment of the Human Immune Response to Immunomodulators in Next Generation HIS Mice

10:20 am Pharmacodynamic Assessment of Bispecific IgM Antibody Using BRGSF-HIS Mice

Synopsis

  • Introduction: Generation of BRGSF-HIS mice 
  • Introduction: IgM antibody 
  • Data slides: PD assessment data 

10:40 am Humanized Mouse Models in the Development of PD-1 Agonists

  • Kevin Otipoby Vice President of Research, Immunology, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.
  • Lindsay Edwards Principal Scientist, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.

Synopsis

Our talk will explore the development of PD-1 agonists in:

  • Xenogeneic graft versus host disease
  • Genetically engineered models
  • Human hematopoietic stem cell engrafted models

11:00 am BRGSF-HIS Mice: A New Model to Assess the Human Immune Response to Immunomodulators

  • Kader Thiam SVP, Discovery, Preclinical Models & Services, genOway

Synopsis

  • Features of the human lymphoid and myeloid immune cells developed in the BRGSF-HIS mice after reconstitution with hCD34+ cells 
  • Human immune response in a context of tumor growth & anti-tumor treatment  

11:20 am Panel Discussion: What Does the Next Gen Humanized Models Need to Look Like?

  • Kader Thiam SVP, Discovery, Preclinical Models & Services, genOway
  • Niina Veitonmaki Head of Biology, Aelin Therapeutics
  • Kevin Otipoby Vice President of Research, Immunology, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.
  • Lindsay Edwards Principal Scientist, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.
  • Poonam Yakundi Scientist II, IGM Biosciences
  • Annie An Associate Director, Crown Bioscience, Inc.
  • Dean Campbell Director, Scientific Engagement, Crown Bioscience, Inc.

Synopsis

In this interactive panel discussions, we will feature IO experts across pharma, biotech and CRO to discuss common challenges and solutions, including: 

  • How to design and validate a complex genetically engineered mouse model? 
  • Costs and reproducibility of humanized models  
  • Quality control and how to minimize variability?  
  • Flexibility – off the shelf vs customized models? 

12:00 pm Chair’s Closing Remarks & End of Meeting